257 related articles for article (PubMed ID: 17034932)
1. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow.
Foresta C; Caretta N; Lana A; De Toni L; Biagioli A; Vinanzi C; Ferlin A
Eur Urol; 2007 May; 51(5):1411-7; discussion 1417-9. PubMed ID: 17034932
[TBL] [Abstract][Full Text] [Related]
2. Effect of vardenafil on endothelial progenitor cells in hypogonadotrophic hypogonadal patients: role of testosterone treatment.
Foresta C; Di Mambro A; Caretta N; De Toni L; Zuccarello D; Ferlin A
Clin Endocrinol (Oxf); 2009 Sep; 71(3):412-6. PubMed ID: 19094070
[TBL] [Abstract][Full Text] [Related]
3. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway.
Sahara M; Sata M; Morita T; Nakajima T; Hirata Y; Nagai R
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1315-24. PubMed ID: 20413734
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.
Kloner RA
Am J Cardiol; 2005 Dec; 96(12B):42M-46M. PubMed ID: 16387566
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta.
Korkmaz S; Radovits T; Barnucz E; Neugebauer P; Arif R; Hirschberg K; Loganathan S; Seidel B; Karck M; Szabó G
Eur J Pharmacol; 2009 Aug; 615(1-3):155-62. PubMed ID: 19482016
[TBL] [Abstract][Full Text] [Related]
6. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
7. The effect of vardenafil on endothelial function of brachial and cavernous arteries.
Mazo E; Gamidov S; Iremashvili V
Int J Impot Res; 2006; 18(5):464-9. PubMed ID: 16482199
[TBL] [Abstract][Full Text] [Related]
8. Vardenafil treatment for erectile dysfunction.
Crowe SM; Streetman DS
Ann Pharmacother; 2004 Jan; 38(1):77-85. PubMed ID: 14742800
[TBL] [Abstract][Full Text] [Related]
9. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans.
Foresta C; Lana A; Cabrelle A; Ferigo M; Caretta N; Garolla A; Palù G; Ferlin A
Int J Impot Res; 2005; 17(4):377-80. PubMed ID: 15829988
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of vardenafil (a PDE-5 Inhibitor) on corpus cavernosal smooth muscle relaxation in diabetic rabbits.
Lau DH; Mumtaz FH; Mikhailidis DP; Thompson CS
Urol Int; 2009; 82(1):101-7. PubMed ID: 19172107
[TBL] [Abstract][Full Text] [Related]
11. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction.
Foresta C; Ferlin A; De Toni L; Lana A; Vinanzi C; Galan A; Caretta N
Int J Impot Res; 2006; 18(5):484-8. PubMed ID: 16541115
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5).
Salvi F; Sarzani R; Giorgi R; Donatelli G; Pietrucci F; Micheli A; Baldoni M; Minardi D; Dessì-Fulgheri P; Polito M; Muzzonigro G; Rappelli A
Int J Impot Res; 2004 Oct; 16(5):412-7. PubMed ID: 15175637
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction].
Jin J; Guo Y
Zhonghua Nan Ke Xue; 2004 Sep; 10(9):711-6. PubMed ID: 15497717
[TBL] [Abstract][Full Text] [Related]
14. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.
Filippi S; Morelli A; Sandner P; Fibbi B; Mancina R; Marini M; Gacci M; Vignozzi L; Vannelli GB; Carini M; Forti G; Maggi M
Endocrinology; 2007 Mar; 148(3):1019-29. PubMed ID: 17138653
[TBL] [Abstract][Full Text] [Related]
15. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
Zumbé J; Porst H; Sommer F; Grohmann W; Beneke M; Ulbrich E
Eur Urol; 2008 Jul; 54(1):204-10. PubMed ID: 18395326
[TBL] [Abstract][Full Text] [Related]
16. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels.
Jarvi K; Dula E; Drehobl M; Pryor J; Shapiro J; Seger M
J Urol; 2008 Mar; 179(3):1060-5. PubMed ID: 18206950
[TBL] [Abstract][Full Text] [Related]
17. Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs.
Angulo J; Cuevas P; Cuevas B; Bischoff E; Sáenz de Tejada I
Int J Impot Res; 2003 Apr; 15(2):137-41. PubMed ID: 12789394
[TBL] [Abstract][Full Text] [Related]
18. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil and vardenafil.
Neumeyer K; Kirkpatrick P
Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
[No Abstract] [Full Text] [Related]
20. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
